LabCorp Holdings Inc. (LH) — ESG & Values Scores

Environment story

LabCorp demonstrates moderate environmental performance with disclosed Scope 1&2 reduction targets aligned with Science Based Targets (SBTs) approved in 2023. However, Scope 3 emissions disclosure is limited, and the company relies significantly on renewable energy certificates rather than direct operational decarbonization. The 2025 renewable electricity commitment (100% for BLS labs) is notable but does not extend across all operations. No major environmental controversies or fines are disclosed in the 10-K risk factors, though the company acknowledges regulatory compliance risks related to hazardous waste and environmental health & safety laws. Capital expenditure for sustainability infrastructure is not separately quantified.

Criticisms on file

Undisclosed Scope 3 emissions despite significant supply-chain dependencies (BLS relies on third-party suppliers for laboratory materials, specialized animal populations, and transportation); risk factor acknowledges 'disruptions in supply chains' but no climate-related emissions metrics disclosed
Source: LH_10k.txt, Risk Factors section - 'Changes or disruption in services, supplies, or transportation provided by third parties'
Heavy reliance on renewable energy certificates (RECs) rather than direct operational decarbonization; BLS 100% renewable target achieved via certificates, not owned generation or power purchase agreements
Source: LH_proxy.txt, Corporate Responsibility Highlights - '100% of global biopharma laboratory services laboratories are on renewable electricity and/or renewable energy certificates in 2025'
Compliance risks with environmental health and safety laws acknowledged; company subject to regulations for handling, transportation, and disposal of medical specimens, infectious and hazardous waste, and radioactive materials; potential fines and enforcement actions not detailed
Source: LH_10k.txt, Risk Factors - 'Failure to comply with U.S., state, local, or international environmental, health and safety laws and regulations...could result in fines, penalties and loss of licensure'

Disclosed initiatives

Science-Based Targets (SBTs)

Received SBT approval in 2023 for combined Scope 1 and 2 emissions reduction

Demonstrates commitment to validated climate targets; specific reduction % and timeline not disclosed in documents
Fleet Efficiency Improvement

Improved fuel efficiency of U.S. vehicle fleet by 10% versus 2021; all U.S. courier fleet orders in 2025 involve hybrid and electric vehicles

Direct operational decarbonization in transportation; represents partial mode shift away from fossil fuels
Renewable Energy Transition

100% of BLS labs on renewable electricity or renewable energy certificates (2025)

Scope 2 elimination for BLS segment; reliance on certificates suggests offset-based approach rather than direct renewable build
Environmental Sustainability Goals 2025

38% reduction in CO2 emissions per million dollars of revenue versus 2020

Revenue-adjusted emissions reduction demonstrates operational efficiency gains
EcoVadis and CDP Ratings

Earned EcoVadis Silver rating; CDP Climate Change A- rating and A supplier engagement score

Third-party validation of environmental performance and supply-chain transparency

Social story

LabCorp demonstrates moderate-to-strong social performance with disclosed diversity initiatives and active labor governance engagement. CEO-to-worker pay ratio is not explicitly disclosed; based on proxy data, CEO Schechter compensation approximates upper-quartile range but specifics unavailable. Board and executive leadership diversity shows gender and ethnic representation above 30% threshold. Union presence is limited ('party to a limited number of collective bargaining agreements'); no active strikes or major labor disputes reported in 2025. Supply-chain human-rights audits are not detailed; company acknowledges labor law compliance risks but no evidence of unmitigated hazards in disclosed sourcing. Turnover rates are not quantified in public documents.

Criticisms on file

Unfavorable labor environments and unionization risks acknowledged; company states potential for labor unrest, strikes, work stoppages, and higher labor costs if unionization increases; no specific 2025 incidents disclosed but risk factor emphasizes ongoing exposure
Source: LH_10k.txt, Risk Factors - 'Unfavorable labor environments, union strikes, work stoppages, union or works council negotiations, or failure to comply with labor or employment laws could adversely affect the Company's operations'
CEO pay ratio not disclosed; proxy shows CEO Schechter received total 2025 compensation in upper range but specific worker ratio unavailable for comparison against 200:1 threshold
Source: LH_proxy.txt - CEO pay ratio disclosure absent from proxy statement; summary compensation table present but median worker pay not disclosed
Supply-chain human-rights and labor standards not formally audited or disclosed; company acknowledges dependence on third-party suppliers for critical materials and services but does not publish supply-chain labor or ethics audit results
Source: LH_10k.txt, Risk Factors - 'Changes or disruption in services, supplies, or transportation provided by third parties...the Company remains dependent on third parties for critical supplies and services'

Disclosed initiatives

Board Diversity and Inclusion

7 of 10 independent director nominees are gender or ethnically/racially diverse; Directors span ages 47-70; Board composition intentionally cultivated to be inclusive

Exceeds 30% diversity threshold; demonstrates commitment to board-level representation
Executive Succession and Development

CHC Committee oversees CEO and key executive succession planning; discussed with and without CEO present in executive sessions

Formal succession governance in place; reduces talent risk and retention uncertainty
Director Orientation and Development

Orientation programs for new directors covering strategic plans, governance, key policies; continuing education for all directors

Supports leadership capability and compliance awareness
Labor and Employment Law Compliance

Company acknowledges obligations under labor laws including wage-and-hour, OFCCP compliance, workplace harassment and discrimination prevention

Demonstrates awareness and commitment to legal compliance; no enforcement actions disclosed
Employee Health and Safety Oversight

Board oversight of employee health and safety; Quality and Compliance Committee monitors operational compliance

Formal governance structure for occupational safety

Governance story

LabCorp exhibits strong governance practices with 91% board independence (10 of 11 directors independent), annual director election by majority vote, and 100% independent board committees. No dual-class share structure exists. Board composition shows active refreshment with 6 of 10 independent directors appointed within past 7 years. Lobbying expenditure is not quantified in SEC filings; company acknowledges oversight of lobbying and government relations but does not disclose annual spend or specific targets. No major active antitrust, consumer-safety, or financial-fraud regulatory proceedings are disclosed in the 10-K; however, company faces ongoing litigation including the Ravgen patent case ($272M verdict + $100M enhanced damages + post-verdict supplemental damages + ongoing royalties). Leadership transition risk mitigated by formal succession planning. Shareholders retain written-consent and special-meeting call rights.

Criticisms on file

Ravgen patent infringement litigation: October 2020 lawsuit filed; September 2022 jury verdict of $272M in favor of Ravgen; May 2023 court awarded additional enhanced damages of $100M; January 2025 court awarded post-verdict supplemental damages of $2.6M, ongoing royalty of $100 per test through patent life, pre- and post-judgment interest, and other relief; company disputes verdict and pursuing appeal
Source: LH_10k.txt, Legal Matters - 'Failure to successfully obtain, maintain, enforce, or defend intellectual property rights' section detailing Ravgen case
Undisclosed lobbying expenditure; company acknowledges 'Oversight of Company lobbying and political contributions' as governance practice but does not quantify annual spend or disclose specific targets for climate or consumer-protection deregulation influence
Source: LH_proxy.txt, Corporate Governance - Lobbying spending amount not specified in proxy or 10-K
Cybersecurity and data breach litigation risk; AMCA Incident (American Medical Collection Agency breach) resulted in costs, pending and threatened litigation, and regulatory inquiries; company acknowledges heightened cybersecurity threat landscape including ransomware, data breaches, phishing; ongoing exposure to class actions and regulatory penalties
Source: LH_10k.txt, Risk Factors - 'Failure to maintain the security of customer-related information...The AMCA Incident resulted in costs, pending and threatened litigation, and regulatory inquiries'
Multiple qui tam (False Claims Act) suits possible; company acknowledges suits brought under False Claims Act and comparable state laws are 'an inevitable part of doing business in the healthcare field today'; no specific active cases disclosed but potential liability remains
Source: LH_10k.txt, Critical Accounting Estimates - Legal Contingencies section

Disclosed initiatives

Annual Director Election and Majority Voting

All directors elected annually by majority vote; no staggered board; plurality standard applies in contested elections

Ensures regular accountability and shareholder engagement; no entrenchment mechanisms
Board Independence and Committee Composition

91% board independence; all Audit, Compensation & Human Capital, Quality & Compliance, and Nominating & Governance committees composed of 100% independent directors

Meets or exceeds NYSE Listing Standards for independence; robust oversight structure
Lead Independent Director with Defined Role

Dr. Garheng Kong serves as Vice Chairman and Lead Independent Director with clearly defined responsibilities; new Lead Director appointed in 2023

Independent director leadership balances CEO/Chair combination; facilitates executive sessions
Active Board Refreshment and Diversity

6 of 10 independent director nominees appointed within past 7 years; directors span ages 47-70; 64% of board is gender or ethnically/racially diverse

Balances institutional knowledge with fresh perspectives; reduces groupthink risk
Shareholder Rights and Engagement

Shareholders can act by written consent; 10% shareholders can call special meetings; proxy access allows eligible shareholders (3%+ held 3+ years) to nominate directors; 2025 outreach to shareholders representing >80% of voting shares

Strong shareholder protection mechanisms; regular dialogue on governance, compensation, and corporate responsibility
Executive Equity Ownership Guidelines

CEO required to hold 6x annual base salary in stock; EVPs required to hold 3x base salary; independent directors required to hold 5x annual director retainer

Aligns executive and director interests with long-term shareholder value
Anti-Hedging, Clawback, and Anti-Pledging Policies

Company maintains policies restricting hedging, pledging of securities, and requiring recoupment of incentive compensation in specified circumstances

Reduces agency risk and ensures compensation discipline
Executive Compensation Oversight

CHC Committee annually reviews compensation philosophy, peer benchmarking, and pay-for-performance alignment; say-on-pay advisory votes conducted annually (92% approval in 2025)

Strong accountability for executive pay decisions; shareholders retain advisory input

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of LabCorp Holdings Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open LabCorp Holdings Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)